Published in:
01-12-2014 | Original Article
MRI with Gadoxetate Disodium for Colorectal Liver Metastasis: Is It the New “Imaging Modality of Choice”?
Published in: Journal of Gastrointestinal Surgery | Issue 12/2014
Login to get accessAbstract
Background
Accurate detection of colorectal liver metastasis is paramount in the role of management. This study aims to compare magnetic resonance imaging (MRI) with gadoxetate disodium (a hepatocyte-specific agent—Eovist®) to triple-phase enhanced computed tomography in detecting colorectal liver metastases.
Methods
A retrospective chart analysis of 30 patients from 2011 to 2013 with colorectal liver metastases was performed. Patients with more than 6 weeks or two cycles of chemotherapy between the two imaging modalities were excluded. The number of lesions identified on triple-phase enhanced computed tomography vs. MRI with Eovist® was compared.
Results
Of the 30 patients that met the inclusion criteria, 12 (40 %) patients had more lesions identified on MRI with Eovist® compared to triple-phase enhanced computed tomography. Eighteen (60 %) had no change in the number of lesions identified. When MRI with Eovist® detected more lesions, the mean number of additional lesions detected was 1.5. Eovist® MRI changed the surgical management in 36.7 % of patients.
Conclusion
MRI with Eovist® is superior to enhanced computed tomography in identifying colorectal liver metastases. The increased number of lesion identified on MRI with Eovist® can profoundly change the surgeon’s management. It should be considered the “imaging modality of choice” in preoperative imaging for liver metastases in these patients.